COVID-19 肺炎后进行性多灶性白质脑病意外恶化。
Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia.
机构信息
Department of Neurology, Brugmann University Hospital and Free University of Brussels (ULB), Brussels, Belgium.
Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
出版信息
J Neurovirol. 2021 Jun;27(3):510-513. doi: 10.1007/s13365-021-00980-2. Epub 2021 Apr 19.
Progressive multifocal leucoencephalopathy is a serious side effect of natalizumab, a humanized monoclonal antibody approved for the treatment of multiple sclerosis. Here, we report a case of unexpected worsening of natalizumab-related progressive multifocal leucoencephalopathy following COVID-19. After natalizumab discontinuation, a slight neurological improvement was observed, but, two months later the patient was admitted to the hospital because of neurological deterioration and COVID-19 mild pneumonia. Except for SARS-CoV-2 infection, no other potential factors of neurological worsening were identified. Thus, we pose the hypothesis that SARS-CoV-2 was instrumental in the progressive multifocal leucoencephalopathy deterioration.
进行性多灶性白质脑病是那他珠单抗的一种严重副作用，那他珠单抗是一种已被批准用于治疗多发性硬化症的人源化单克隆抗体。在这里，我们报告了一例 COVID-19 后那他珠单抗相关进行性多灶性白质脑病意外恶化的病例。停止使用那他珠单抗后，患者的神经功能略有改善，但两个月后，患者因神经功能恶化和 COVID-19 轻度肺炎住院。除了 SARS-CoV-2 感染外，未发现其他潜在的神经恶化因素。因此，我们假设 SARS-CoV-2 是进行性多灶性白质脑病恶化的原因。
Zotero 插件